The Thromboembolism and Bleeding Event in Patients Receiving Warfarin, Dabigatran, or Rivaroxaban in Nonvalvular Atrial Fibrillation
DOI:
https://doi.org/10.30595/pharmacy.v18i2.13315Keywords:
Bleeding event, dabigatran, nonvalvular atrial fibrillation, prevalence, rivaroxaban, thromboembolism, warfarinAbstract
Increasing in trend of Dabigatran and Rivaroxaban usage every year in Hospital Sultanah Nur Zahirah (HSNZ) has raised concerns regarding their effectiveness and safety compared to Warfarin. Therefore, we investigated the prevalence of thromboembolism (stroke or systemic embolism) and bleeding events in patients receiving Warfarin, Dabigatran or Rivaroxaban in our setting. This retrospective cohort study involved patients with nonvalvular atrial fibrillation who were started on Warfarin, Dabigatran or Rivaroxaban from January 1, 2014 to December 31, 2018. To fulfil inclusion criteria, patients must be on treatment for at least one year and for Warfarin group, at least 65% of Time in Therapeutic Range (TTR) should be achieved. Data were collected from Warfarin registration book, drug usage record card and Hospital Information System. 142 patients (Warfarin, n=98; Dabigatran, n=30; Rivaroxaban, n=14) with mean age of 68±8.7 years old were included in the study. Majority of them were male, Malay and non-smoker with 57.0%, 97.2% and 95.8% respectively. Upon study enrolment, all patients were at moderate risk of stroke (median CHA2DS2-VASc score=3) and low risk of bleeding (median HAS-BLED score=2). One Ischemic stroke was identified in each group of Rivaroxaban 15 mg and Dabigatran 150 mg. Four bleeding events occurred in all groups except for Dabigatran group that were hematuria, gum bleeding and upper gastrointestinal bleeding. Thromboembolism and bleeding events still occur in all groups. However, the prevalence is small in our setting with the percentage of 1.4% and 2.8% respectively. The events mostly attributed by the predisposed risk factors.
References
January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al; 2014. Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. doi: 10.1016/j.jacc.2014.03.022.
Xiaoxi Yao, PhD; Neena S. Abraham, MD, MSCE; Lindsey R. Sangaralingham, MPH; M. Fernanda Bellolio, MD, MS; Robert D. McBane, MD; Nilay D. Shah, PhD; Peter A. Noseworthy MD, 2019. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, et al. 2008. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther.; 84:326–331. doi: 10.1038/.
Madan, S., Shah, S., Partovi, S., & Parikh, S. A. (2014). Use of novel oral anticoagulant agents in atrial fibrillation: current evidence and future perspective. Cardiovascular diagnosis and therapy, 4(4), 314-23.
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al; 2019. Re-Ly Steering Committee and Investigators, Dabigatran versus warfarin in patients with atrial fibrillation; 361:1139–1151. N Engl J Med., doi: 10.1056/NEJMoa0905561.
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al; 2011. ROCKET AF Investigators. N Engl J Med, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.365:883–891. doi: 10.1056/ NEJMoa1009638.
David J cangemi, Timothy Krill, Rick WeideMAN, Daisha Cipher, Stuart J Spechler, Linda A Feagins,2017. A Comparison of the Rate of Gastrointestinal Bleeding in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin, 112(5):734-739. doi: 10.1038/ajg.2017.39.
Linda A. Feagins, Rick A. Weideman, 2018. GI Bleeding Risk of DOACs Versus Warfarin: Is Newer Better? Digestive Diseases and Sciences (2018) 63:1675–1677.
Amelia K. Boehme, Charles Esenwa and Mitchell S.V. Elkind, 2017. Stroke Risk Factors, Genetics, and Prevention https://doi.org/10.1161/ CIRCRESAHA.
Sheu, J.J, 2010. Overactive Thyroid May Raise Early Stroke Risk, Stroke: Journal of the American Heart Association.
C Becattini, M Giustozzi, M G Ranalli, G Bogliari, F Cianella, M Verso, G Agnelli, M C Vedovati, 2018. Variation of renal function over time is associated with major bleeding in patients treated with direct oral anticoagulants for atrial fibrillation, DOI: 10.1111/ jth.13985.
Morten L. Hansen, MD, PhD Rikke Sørensen, MD Mette T. Clausen, 2010. Risk of Bleeding with Single, Dual, or Triple Therapy with Warfarin, Aspirin, and Clopidogrel in Patients with Atrial Fibrillation, doi:10.1001/archinternmed.2010.27.
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
